

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 Madrid

In Granada, 9 June 2014

RELEVANT FACT OF NEURON BIOPHARMA, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB, Neuron Biopharma S.A. (hereinafter “NEURON” or the “Company”) hereby informs that:

The capital increase as agreed by the Board of Directors of NEURON on 20 February 2014, in accordance to the delegation conferred in the General Shareholders’ Meeting held on 23 June 2013, has been fully subscribed, thus issuing 2 312 500 new shares at an emission price equivalent to their nominal value amounting 1 euro per share. Consequently the capital increase amounted to Euros 2 312 500. Additionally, 814 353 shares equivalent to Euro 814 353 were requested representing a 35.2% with regard to the amount of the capital increase and which finally could not be submitted.

The new shares are ordinary shares and belong to the same class and series than those currently outstanding shares of the company and carry the same rights and obligations than the former ones. They are represented through book-entries managed by the company Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A. “Iberclear” and by its participating entities in the terms established in the legislation in force in each moment.

It is important to mention that the admission to official trading of the total amount of shares is requested to the MAB-EE.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors